The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Personalizing treatment for MPNs by selecting between JAK inhibitors
Alex Rampotas, MBBS, MRCP, University College London, London, UK, outlines the treatment options that have become available for patients with myeloproliferative neoplasms (MPNs), namely the JAK inhibitors (ruxolitinib, fedratinib, momelotinib, and pacritinib). Dr Rampotas notes that treatment can be personalized to each patient, as these agents have unique features. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
We are quite lucky in the MPN field that we’ve had many new treatments becoming available in the last few years with ruxolitinib being the first one and more recently fedratinib and momelotinib and maybe pacritinib would also become available in the UK soon. I think the more treatment options we have available, we are able to personalize the therapy and identify the best drug option for each patient...
We are quite lucky in the MPN field that we’ve had many new treatments becoming available in the last few years with ruxolitinib being the first one and more recently fedratinib and momelotinib and maybe pacritinib would also become available in the UK soon. I think the more treatment options we have available, we are able to personalize the therapy and identify the best drug option for each patient.
So all of these, although they are all JAK inhibitors, they also have some unique features. They suppress the JAK-STAT pathway in a slightly different way. Momelotinib, for example, is better for patients that have anemia, while ruxolitinib is probably a more potent inhibitor of the JAK-STAT pathway. And these drugs, although we still don’t know how much they will improve overall survival, we know that they definitely improve symptoms they reduce the spleen size and in the case of momelotinib they improve anemia responses which is very important because if we reduce the transfusion burden that has a huge effect on the quality of life of patients. So I think as more of these treatments become available we were able to find the best sequence of these treatments and the best one that would fit each patient profile and that would transform our practice because we’ll be able to select the right treatment approach for each patient individually.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
